---
title: "12 Health Care Stocks Moving In Thursday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295796603.md"
description: "In Thursday's pre-market session, several healthcare stocks saw significant movement. Gainers included Liminatus Pharma (+55.9%), LENSAR (+20.19%), NRC Health (+16.44%), Omeros (+15.99%), Cullinan Therapeutics (+12.27%), and Journey Medical (+11.04%). Losers featured Outlook Therapeutics (-25.7%), Valion Bio (-25.67%), Curis (-19.17%), Abeona Therapeutics (-17.97%), Contineum Therapeutics (-17.49%), and Dermata Therapeutics (-15.22%). Many price movements coincided with Q2 earnings reports."
datetime: "2026-08-13T12:05:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295796603.md)
  - [en](https://longbridge.com/en/news/295796603.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295796603.md)
---

# 12 Health Care Stocks Moving In Thursday's Pre-Market Session

### Gainers

-   **Liminatus Pharma** (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million.
-   **LENSAR** (NASDAQ:LNSR) shares increased by 20.19% to $7.56. The company's market cap stands at $77.2 million. The company's, Q2 earnings came out today.
-   **NRC Health** (NASDAQ:NRC) stock increased by 16.44% to $24.0. The market value of their outstanding shares is at $455.8 million.
-   **Omeros** (NASDAQ:OMER) shares moved upwards by 15.99% to $15.9. The company's market cap stands at $992.2 million. As per the news, the Q2 earnings report came out yesterday.
-   **Cullinan Therapeutics** (NASDAQ:CGEM) stock rose 12.27% to $22.0. The market value of their outstanding shares is at $1.2 billion.
-   **Journey Medical** (NASDAQ:DERM) stock rose 11.04% to $7.14. The company's market cap stands at $177.0 million. The company's, Q2 earnings came out yesterday.

### Losers

-   **Outlook Therapeutics** (NASDAQ:OTLK) stock decreased by 25.7% to $0.82 during Thursday's pre-market session. The company's market cap stands at $205.6 million.
-   **Valion Bio** (NASDAQ:VBIO) shares declined by 25.67% to $0.17.
-   **Curis** (NASDAQ:CRIS) stock declined by 19.17% to $1.35. The market value of their outstanding shares is at $3.4 million.
-   **Abeona Therapeutics** (NASDAQ:ABEO) stock declined by 17.97% to $6.12. The market value of their outstanding shares is at $425.1 million. As per the news, the Q2 earnings report came out today.
-   **Contineum Therapeutics** (NASDAQ:CTNM) stock declined by 17.49% to $12.36. The company's market cap stands at $563.5 million.
-   **Dermata Therapeutics** (NASDAQ:DRMA) shares declined by 15.22% to $1.17. The company's market cap stands at $5.5 million. As per the press release, Q2 earnings came out 2 days ago. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ABEO.US](https://longbridge.com/en/quote/ABEO.US.md)
- [NRC.US](https://longbridge.com/en/quote/NRC.US.md)
- [CGEM.US](https://longbridge.com/en/quote/CGEM.US.md)
- [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md)
- [DRMAW.US](https://longbridge.com/en/quote/DRMAW.US.md)
- [CTNM.US](https://longbridge.com/en/quote/CTNM.US.md)
- [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md)
- [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md)
- [DERM.US](https://longbridge.com/en/quote/DERM.US.md)
- [LIMN.US](https://longbridge.com/en/quote/LIMN.US.md)
- [OTLK.US](https://longbridge.com/en/quote/OTLK.US.md)
- [OMER.US](https://longbridge.com/en/quote/OMER.US.md)
- [LNSR.US](https://longbridge.com/en/quote/LNSR.US.md)
- [LIMNW.US](https://longbridge.com/en/quote/LIMNW.US.md)

## Related News & Research

- [OTLK: FDA approval and launch plans for LYTENAVA drive growth prospects amid improved financials](https://longbridge.com/en/news/295929118.md)
- [Abeona Therapeutics Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/295818848.md)
- [Cullinan Therapeutics, Inc. $CGEM Shares Bought by The Manufacturers Life Insurance Company](https://longbridge.com/en/news/295767041.md)
- [Cullinan Reports Positive Phase 3 Zipalertinib Lung Cancer Data](https://longbridge.com/en/news/295786559.md)
- [Abeona Therapeutics Q2 net loss widens, misses analyst expectations](https://longbridge.com/en/news/295791975.md)